Cargando…

Peptide Characterization and Functional Stability of a Partially Hydrolyzed Whey-Based Formula over Time

Human clinical trials have shown that a specific partially hydrolyzed 100% whey-based infant formula (pHF-W) reduces AD risk in the first yeast of life. Meta-analyses with a specific pHF-W (pHF-W1) confirm a protective effect while other meta-analyses pooling different pHF-W show conflicting results...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourdeau, Tristan, Affolter, Michael, Dupuis, Lénaïck, Panchaud, Alexandre, Lahrichi, Sabine, Merminod, Loraine, Martin-Paschoud, Christine, Adams, Rachel, Nutten, Sophie, Blanchard, Carine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465316/
https://www.ncbi.nlm.nih.gov/pubmed/34578889
http://dx.doi.org/10.3390/nu13093011
_version_ 1784572841507684352
author Bourdeau, Tristan
Affolter, Michael
Dupuis, Lénaïck
Panchaud, Alexandre
Lahrichi, Sabine
Merminod, Loraine
Martin-Paschoud, Christine
Adams, Rachel
Nutten, Sophie
Blanchard, Carine
author_facet Bourdeau, Tristan
Affolter, Michael
Dupuis, Lénaïck
Panchaud, Alexandre
Lahrichi, Sabine
Merminod, Loraine
Martin-Paschoud, Christine
Adams, Rachel
Nutten, Sophie
Blanchard, Carine
author_sort Bourdeau, Tristan
collection PubMed
description Human clinical trials have shown that a specific partially hydrolyzed 100% whey-based infant formula (pHF-W) reduces AD risk in the first yeast of life. Meta-analyses with a specific pHF-W (pHF-W1) confirm a protective effect while other meta-analyses pooling different pHF-W show conflicting results. Here we investigated the molecular composition and functional properties of the specific pHF-W1 as well as the stability of its manufacturing process over time. This specific pHF-W1 was compared with other pHF-Ws. We used size exclusion chromatography to characterize the peptide molecular weight (MW), a rat basophil degranulation assay to assess the relative level of beta-lactoglobulin (BLG) allergenicity and a preclinical model of oral tolerance induction to test prevention of allergic sensitization. To analyze the exact peptide sequences before and after an HLA binding assay, a mass cytometry approach was used. Peptide size allergenicity and oral tolerance induction were conserved across pHF-W1 batches of production and time. The median MW of the 37 samples of pHF-W1 tested was 800 ± 400 Da. Further oral tolerance induction was observed using 10 different batches of the pHF-W1 with a mean reduction of BLG-specific IgE levels of 0.76 log (95% CI = −0.95; −0.57). When comparing pHF-W1 with three other formulas (pHF-W2 3 and 4), peptide size was not necessarily associated with allergenicity reduction in vitro nor oral tolerance induction in vivo as measured by specific IgE level (p < 0.05 for pHF-W1 and 2 and p = 0.271 and p = 0.189 for pHF-W3 and 4 respectively). Peptide composition showed a limited overlap between the formulas tested ranging from 11.7% to 24.2%. Furthermore nine regions in the BLG sequence were identified as binding HLA-DR. In conclusion, not all pHF-Ws tested have the same peptide size distribution decreased allergenicity and ability to induce oral tolerance. Specific peptides are released during the different processes used by different infant formula producers.
format Online
Article
Text
id pubmed-8465316
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84653162021-09-27 Peptide Characterization and Functional Stability of a Partially Hydrolyzed Whey-Based Formula over Time Bourdeau, Tristan Affolter, Michael Dupuis, Lénaïck Panchaud, Alexandre Lahrichi, Sabine Merminod, Loraine Martin-Paschoud, Christine Adams, Rachel Nutten, Sophie Blanchard, Carine Nutrients Article Human clinical trials have shown that a specific partially hydrolyzed 100% whey-based infant formula (pHF-W) reduces AD risk in the first yeast of life. Meta-analyses with a specific pHF-W (pHF-W1) confirm a protective effect while other meta-analyses pooling different pHF-W show conflicting results. Here we investigated the molecular composition and functional properties of the specific pHF-W1 as well as the stability of its manufacturing process over time. This specific pHF-W1 was compared with other pHF-Ws. We used size exclusion chromatography to characterize the peptide molecular weight (MW), a rat basophil degranulation assay to assess the relative level of beta-lactoglobulin (BLG) allergenicity and a preclinical model of oral tolerance induction to test prevention of allergic sensitization. To analyze the exact peptide sequences before and after an HLA binding assay, a mass cytometry approach was used. Peptide size allergenicity and oral tolerance induction were conserved across pHF-W1 batches of production and time. The median MW of the 37 samples of pHF-W1 tested was 800 ± 400 Da. Further oral tolerance induction was observed using 10 different batches of the pHF-W1 with a mean reduction of BLG-specific IgE levels of 0.76 log (95% CI = −0.95; −0.57). When comparing pHF-W1 with three other formulas (pHF-W2 3 and 4), peptide size was not necessarily associated with allergenicity reduction in vitro nor oral tolerance induction in vivo as measured by specific IgE level (p < 0.05 for pHF-W1 and 2 and p = 0.271 and p = 0.189 for pHF-W3 and 4 respectively). Peptide composition showed a limited overlap between the formulas tested ranging from 11.7% to 24.2%. Furthermore nine regions in the BLG sequence were identified as binding HLA-DR. In conclusion, not all pHF-Ws tested have the same peptide size distribution decreased allergenicity and ability to induce oral tolerance. Specific peptides are released during the different processes used by different infant formula producers. MDPI 2021-08-28 /pmc/articles/PMC8465316/ /pubmed/34578889 http://dx.doi.org/10.3390/nu13093011 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bourdeau, Tristan
Affolter, Michael
Dupuis, Lénaïck
Panchaud, Alexandre
Lahrichi, Sabine
Merminod, Loraine
Martin-Paschoud, Christine
Adams, Rachel
Nutten, Sophie
Blanchard, Carine
Peptide Characterization and Functional Stability of a Partially Hydrolyzed Whey-Based Formula over Time
title Peptide Characterization and Functional Stability of a Partially Hydrolyzed Whey-Based Formula over Time
title_full Peptide Characterization and Functional Stability of a Partially Hydrolyzed Whey-Based Formula over Time
title_fullStr Peptide Characterization and Functional Stability of a Partially Hydrolyzed Whey-Based Formula over Time
title_full_unstemmed Peptide Characterization and Functional Stability of a Partially Hydrolyzed Whey-Based Formula over Time
title_short Peptide Characterization and Functional Stability of a Partially Hydrolyzed Whey-Based Formula over Time
title_sort peptide characterization and functional stability of a partially hydrolyzed whey-based formula over time
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465316/
https://www.ncbi.nlm.nih.gov/pubmed/34578889
http://dx.doi.org/10.3390/nu13093011
work_keys_str_mv AT bourdeautristan peptidecharacterizationandfunctionalstabilityofapartiallyhydrolyzedwheybasedformulaovertime
AT affoltermichael peptidecharacterizationandfunctionalstabilityofapartiallyhydrolyzedwheybasedformulaovertime
AT dupuislenaick peptidecharacterizationandfunctionalstabilityofapartiallyhydrolyzedwheybasedformulaovertime
AT panchaudalexandre peptidecharacterizationandfunctionalstabilityofapartiallyhydrolyzedwheybasedformulaovertime
AT lahrichisabine peptidecharacterizationandfunctionalstabilityofapartiallyhydrolyzedwheybasedformulaovertime
AT merminodloraine peptidecharacterizationandfunctionalstabilityofapartiallyhydrolyzedwheybasedformulaovertime
AT martinpaschoudchristine peptidecharacterizationandfunctionalstabilityofapartiallyhydrolyzedwheybasedformulaovertime
AT adamsrachel peptidecharacterizationandfunctionalstabilityofapartiallyhydrolyzedwheybasedformulaovertime
AT nuttensophie peptidecharacterizationandfunctionalstabilityofapartiallyhydrolyzedwheybasedformulaovertime
AT blanchardcarine peptidecharacterizationandfunctionalstabilityofapartiallyhydrolyzedwheybasedformulaovertime